AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

14 recruiting trials

for ALK Positive Advanced Malignancies

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC NCT05498064n/a1 site๐Ÿ“ Beijing Peking Union Medical College Hospital ยท Tests: Ensartinib A Phase 1/2 Study of SY-12321 in Patients With ALK-positive Advanced Malignancies NCT07810933Phase 1, Phase 22 sites๐Ÿ“ Guangzhou๐Ÿ“ Nanjing Shouyao Holdings (Beijing) Co. LTD ยท Tests: SY-12321 Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer NCT07415005Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Lorlatinib Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site๐Ÿ“ Guangzhou Guangdong Association of Clinical Trials ยท Tests: Ivonescimab Injection Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC NCT05122806NA46 sites๐Ÿ“ Saint-Denis๐Ÿ“ Aix-en-Provence๐Ÿ“ Amiens Groupe Francais De Pneumo-Cancerologie ยท Tests: RNAseq Alectinib Pharmacokinetic in Patients With NSCLC NCT05713006Phase 1, Phase 21 site๐Ÿ“ Mexico City Instituto Nacional de Cancerologia de Mexico ยท Tests: Alectinib Oral Product A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) NCT07140016Phase 117 sites๐Ÿ“ Fullerton๐Ÿ“ Orange๐Ÿ“ Edwards Astellas Pharma Global Development, Inc. ยท Tests: gilteritinib Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC NCT06092086Phase 21 site๐Ÿ“ Guangzhou Guangdong Association of Clinical Trials ยท Tests: Loratinib Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients NCT06361589n/a1 site๐Ÿ“ Chengdu Sichuan Cancer Hospital and Research Institute ยท Tests: Lorlatinib Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC NCT06765109Phase 3159 sites๐Ÿ“ Glendale๐Ÿ“ Newport Beach๐Ÿ“ Orange Nuvalent Inc. ยท Tests: Neladalkib (NVL-655), Alectinib A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC NCT07491497Phase 1, Phase 216 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Boston TRIANA Biomedicines, Inc. ยท Tests: TRI-611 Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib NCT07374614n/a1 site๐Ÿ“ Shenzhen Peking University Shenzhen Hospital ยท Tests: Iruplinalkib tablets Study of NXP900 With Lorlatinib in ALK+ Lung Cancer NCT07784959Phase 11 site๐Ÿ“ Fairfax Nuvectis Pharma, Inc. ยท Tests: NXP900, Lorlatinib Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib NCT07633626n/a1 site๐Ÿ“ Bogotรก Centro de Tratamiento e Investigaciรณn sobre Cรกncer, Luis Caโ€ฆ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy